PROPOFOL

Product NDC
80830-2365
11-digit product format
808302365
Labeler code
80830
Product ID
80830-2365_37f0add8-759a-4ec9-a147-edef685124e5
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
propofol
Dosage form
INJECTION, EMULSION
Route
INTRAVENOUS
Labeler
Amneal Pharmaceuticals Private Limited
Application
ANDA217525
Marketing category
ANDA
Marketing start
2024-08-16
Substance
PROPOFOL
Active strength
10 mg/mL
Pharmacologic classes
General Anesthesia [PE], General Anesthetic [EPC]
NDC exclude flag
No
Listing certified through
2026-12-31
Current FDA listing
Yes

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A217525-001PROPOFOLPROPOFOL10MG/MLINJECTABLE / INJECTIONAB2024-08-15

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
A217525-001AB

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
PROPOFOLPROPOFOLAmneal Pharmaceuticals Private Limited6833edd6-ba8a-4b97-a872-ab253c64a9032025-05-20Warnings, Adverse reactionsExact identifier

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Serious and sometimes fatal reactions. ( 5.1 ) Microbial Contamination: Strict aseptic technique must be maintained during handling. Propofol injectable emulsion vials are never to be accessed more than once or used on more than one person. Administration should commence promptly and be completed within 12 hours after the vial has been opened. Discard unused drug product. Do not use if contamination is suspected. ( 5.2 ) Cardiovascular depression: Cases of bradycardia, asystole and cardiac arrest have been reported. Pediatric patients are susceptible to this effect, particularly when fentanyl is given concomitantly. ( 5.4 ) 5.1 Anaphylactic and Anaphylactoid Reactions Use of propofol injectable emulsion has been associated with both fatal and life threatening anaphylactic and anaphylactoid reactions. Clinical features of anaphylaxis, including angioedema, bronchospasm, erythema and hypotension, occur rarely following propofol injectable emulsion administration. 5.2 Risks of Microbial Contamination Strict aseptic technique must always be maintained during handling. Propofol injectable emulsion is a single-dose parenteral product (single patient infusion vial) which contains 0.005% disodium edetate (EDTA) to inhibit the rate of growth of microorganisms, for up to 12 hours, in the event of accidental extrinsic contamination. However, propofol injectable emulsion can still support the growth of microorganisms, as it is not an antimicrobially preserved product under USP standards. Do not use if contamination is suspected. Discard unused drug product as directed within the required time limits. There have been reports in which failure to use aseptic technique when handling propofol injectable emulsion was associated with microbial contamination of the product and with fever, infection/sepsis, other life-threatening illness and/or death. Propofol injectable emulsion vials are never to be accessed more than once or used on more than one person. There have been reports, in the literature and other public sources, of the transmission of bloodborne pathogens (such as Hepatitis B, Hepatitis C and HIV) from unsafe injection practices and of the use of propofol vials intended for single use on multiple persons. 5.3 Risks of Pediatric Neurotoxicity Published animal studies demonstrate that the administration of anes...

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling: Hypersensitivity reaction [see Warnings and Precautions (5.1) ] Hypotension and/or bradycardia [see Warnings and Precautions (5.4) ] Propofol Infusion Syndrome [see Warnings and Precautions (5.9) ] In the description below, rates of the more common events represent US/Canadian clinical study results. Less frequent events are also derived from publications and marketing experience in over 8 million patients; there are insufficient data to support an accurate estimate of their incidence rates. These studies were conducted using a variety of premedicants, varying lengths of surgical/diagnostic procedures and various other anesthetic/sedative agents. Most adverse events were mild and transient. Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Anesthesia and MAC Sedation in Adults The following estimates of adverse events for propofol injectable emulsion include data from clinical trials in general anesthesia/MAC sedation (N=2,889 adult patients). The adverse events listed below as probably causally related are those events in which the actual incidence rate in patients treated with propofol injectable emulsion was greater than the comparator incidence rate in these trials. Therefore, incidence rates for anesthesia and MAC sedation in adults generally represent estimates of the percentage of clinical trial patients which appeared to have probable causal relationship. The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established with propofol injectable emulsion during anesthesia (see Table 3 below). During MAC sedation clinical trials, significant respiratory events included cough, upper airway obstruction, apnea, hypoventilation and dyspnea. Anesthesia in Pediatric Patients Generally, the adverse experience profile from reports of 506 propofol injectable emulsion pediatric patients from 6 days through 16 years of age in the US/Canadian anesthesia clinical trials is similar to the profile established with propofol injectable emuls...

adverse reactions table

Anesthesia/MAC SedationICU SedationBody as a Whole:Anaphylaxis/Anaphylactoid reaction perinatal disorder, tachycardia, bigeminy, bradycardia, premature ventricular contractions, hemorrhage, ECG abnormal arrhythmia atrial, fever, extremities pain, anticholinergic syndrome, asthenia, awareness, chest pain, extremities pain, fever, increased drug effect, neck rigidity/stiffness, trunk painFever, sepsis, trunk pain, whole body weaknessCardiovascular:Premature atrial contractions Syncope, hypotension [see also Clinical Pharmacology (12)], tachycardia Nodal, arrhythmia Bradycardia, arrhythmia, atrial fibrillation, atrioventricular heart block, bigeminy, bleeding, bundle branch block, cardiac arrest, ECG abnormal, edema, extrasystole, heart block, hypertension, myocardial infarction, myocardial ischemia, premature ventricular contractions, ST segment depression, supraventricular tachycardia, tachycardia, ventricular fibrillationBradycardia, decreased cardiac output, arrhythmia, atrial fibrillation, bigeminy, cardiac arrest, extrasystole, right heart failure, ventricular tachycardiaCentral Nervous System:Hypertonia/Dystonia, paresthesia, movement, abnormal dreams, agitation, amorous behavior, anxiety, bucking/jerking/thrashing, chills/shivering/clonic/myoclonic movement, combativeness, confusion, delirium, depression, dizziness, emotional lability, euphoria, fatigue, hallucinations, headache, hypotonia, hysteria, insomnia, moaning, neuropathy, opisthotonos, rigidity, seizures, somnolence, tremor, twitchingAgitation, hypotension, hills/shivering, intracranial hypertension, seizures, somnolence, thinking abnormalDigestive:Hypersalivation, nausea, cramping, diarrhea, dry mouth, enlarged parotid, nausea, swallowing, vomitingIleus, liver function abnormalHemic/Lymphatic:Leukocytosis, coagulation disorder, leukocytosisInjection Site:Phlebitis, pruritus, burning/Stinging or pain, hives/itching, phlebitis, redness/discolorationMetabolic/Nutritional:hypomagnesemia, hyperkalemia, hyperlipidemiaBUN increased, creatinine increased, dehydration, hyperglycemia, metabolic acidosis, osmolality increased, hyperlipidemiaMusculoskeletal:MyalgiaNervous:Dizziness, agitation, chills, somnolence DeliriumRespiratory:Wheezing, cough, laryngospasm, hypoxia, apnea, bronchospasm, burning in throat, dyspnea, hiccough, hyperventilation, hypoventilation, pharyngitis, sneezing, tachypnea, upper...

Additional Listing Data#

Finished product
Yes
Brand name base
PROPOFOL
Listing expiration
2026-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
PROPOFOL10 mg/mL

Harmonized Identifiers#

Field, Values table
FieldValues
UniiYI7VU623SF
Rxcui1808217, 1808222, 1808224

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
b5dd1a36-1efc-430d-94c2-9f49a850da5fProduct name620250317
baf7f49c-75b6-496b-a00e-8e766a8e4f03Product name120210127
ebc62596-fc97-4d03-9483-7ba095d25db7Product name120151210
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
80830-2365-1PROPOFOL100 mL in 1 VIALINJECTION, EMULSION1005
80830-2365-7PROPOFOL10 in 1 CARTONINJECTION, EMULSION105

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
80830-2365-1ML - Milliliter80830-2365d8f1da4f-f306-4f4a-a07e-b6c076a4182f12025-01-14
80830-2365-7ML - Milliliter80830-2365ae8bb1a0-1a7a-4265-a915-5c4942492b7a12025-01-14

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
80830-2365PROPOFOL INJECTION, EMULSION [AMNEAL PHARMACEUTICALS PRIVATE LIMITED]5Current NDC, 2 package rows20250522_6833edd6-ba8a-4b97-a872-ab253c64a903.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
1808217propofol 1000 MG in 100 ML InjectionPSN6833edd6-ba8a-4b97-a872-ab253c64a9035
1808224propofol 200 MG in 20 ML InjectionPSN6833edd6-ba8a-4b97-a872-ab253c64a9035
1808222propofol 500 MG in 50 ML InjectionPSN6833edd6-ba8a-4b97-a872-ab253c64a9035
1808217100 ML propofol 10 MG/ML InjectionSCD6833edd6-ba8a-4b97-a872-ab253c64a9035
180822420 ML propofol 10 MG/ML InjectionSCD6833edd6-ba8a-4b97-a872-ab253c64a9035
180822250 ML propofol 10 MG/ML InjectionSCD6833edd6-ba8a-4b97-a872-ab253c64a9035
1808217propofol 1000 MG per 100 ML InjectionSY6833edd6-ba8a-4b97-a872-ab253c64a9035
1808224propofol 200 MG per 20 ML InjectionSY6833edd6-ba8a-4b97-a872-ab253c64a9035
1808222propofol 500 MG per 50 ML InjectionSY6833edd6-ba8a-4b97-a872-ab253c64a9035

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startSampleExclude flagStatus
80830-2365-180830236501100 mL in 1 VIAL100 mlHistorical
80830-2365-78083023650710 VIAL in 1 CARTON (80830-2365-7) / 100 mL in 1 VIAL (80830-2365-1) 10 vial2024-08-16NoNoCurrent